Y-mAbs Therapeutics (YMAB) said Friday it is realigning its internal operations and establishing radiopharmaceuticals and Danyelza units.
The company expects a reduction in its current staffing of up to about 13%, and plans to transfer some jobs to the US from Denmark to better coordinate the advancement of its radiopharmaceutical platform and to make a small adjustment in the Danyelza commercial team.
Y-mAbs also reported preliminary full-year 2024 total net revenue of about $88 million, compared with its previously provided range of $87 million to $95 million. Analysts polled by FactSet expect $88.2 million.
Shares of the company were down by nearly 6% in recent Friday trading.
Price: 7.01, Change: -0.38, Percent Change: -5.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。